UK Biotech Funding Hits Five Year High as AI Drug Discovery Takes Centre Stage
First published onBio Technology Show ↗
London, 20 July 2026: The UK's biotechnology sector has just posted its strongest quarterly fundraising performance in five years, according to fresh figures from the BioIndustry Association (BIA), the trade body representing the country's life sciences industry.
Equity financing for UK biotech companies reached £2.11 billion in the second quarter of 2026, of which £2.05 billion came from venture capital, the highest quarterly VC total the sector has recorded in half a decade.
Much of that headline number was driven by a single deal: Isomorphic Labs, the AI drug discovery spinout backed by Google DeepMind, closed a £1.6 billion Series B round during the quarter. The raise is being read across the industry as a strong vote of confidence in Britain's position at the forefront of AI-driven pharmaceutical research.
However, the momentum extended well beyond a single landmark funding round. Excluding Isomorphic Labs, UK biotech companies still secured £498 million in venture capital during the quarter, almost double the £279 million raised in the same period last year. This reflects broad-based investor confidence across the sector, rather than growth driven by one standout transaction.
The UK also extended its lead as the continent's top destination for biotech venture money, capturing 61% of the £3.3 billion raised across the whole of Europe in Q2, a striking concentration of investor confidence in British life sciences.
BIA chief executive Chris Molloy struck a cautiously optimistic tone, noting that the quarter reflects growing confidence and deal flow across UK biotech, while stressing that public markets need to start recognising and backing the sector at the same pace private investors have.
The latest figures suggest the UK biotech industry is regaining its stride. Supported by growing investor confidence and accelerating advances in AI-driven drug discovery, the sector is well positioned to build on this momentum in the quarters ahead.
Source: BioIndustry Association (BIA), 20 July 2026
